Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People with an advanced solid tumour cancer that fits into one of the following groups: any solid tumour with at least 3 metastatic lesions (areas where cancer has spread) visible on standard scans; a high-grade brain tumour (WHO grade 3 or 4 glioma, confirmed or suspected by scans or biopsy); advanced kidney cancer (clear cell renal cell carcinoma) that has spread, with at least 3 metastatic lesions on standard scans; or prostate cancer that has spread and is no longer responding to hormone therapy, with at least one metastatic lesion visible on standard scans or a specialised PET scan.
- People who are able to understand and are willing to sign a written consent form.
- People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities).
- Women who could potentially become pregnant must have a negative pregnancy test within 72 hours before the baseline procedures.
- People with blood counts and organ function within acceptable ranges, specifically: sufficient white blood cells, platelets, and haemoglobin levels; liver function within acceptable limits; and kidney function above a minimum threshold (confirm exact values with trial site).
Who may not be able to join:
- People with any condition or personal circumstance that, in the investigator's opinion, would make it difficult to follow the study procedures.
- People currently taking certain medications that strongly affect how a particular liver enzyme (CYP3A4) processes drugs (confirm specific medications with trial site).
- People with an active infection that is not under control, or another medical condition that the investigator believes would make participation unsafe.
- People who are pregnant, due to an unknown but potential risk to the unborn child from the study's imaging agent (18F-TRX).
- People who are breastfeeding or chestfeeding, due to an unknown but potential risk to the nursing child from the study's imaging agent (18F-TRX).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rahul Aggarwal, MD, University of California, San Francisco
Phone: (415) 514-8987
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with treatment-emergent adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.